16 research outputs found
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal
cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid
Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic
characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response. We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment.
According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a
favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No
significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However,
in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for
OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively). CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an
alternative when the limitation of RECIST requires additional response analysis techniques.This work was supported by Roche Spain and a Ph.D. grant from the University
of Granada
Down-regulation of SFRP1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma
<p>Abstract</p> <p>Background</p> <p>Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. SFRP1 (the secreted frizzled-related protein 1), a putative tumor suppressor gene mapped onto chromosome 8p12-p11.1, the frequent loss of heterozygosity (LOH) region in human HCC, encodes a Wingless-type (Wnt) signaling antagonist and is frequently inactivated by promoter methylation in many human cancers. However, whether the down-regulation of SFRP1 can contribute to hepatocarcinogenesis still remains unclear.</p> <p>Methods</p> <p>We investigated the expression of SFRP1 through real time RT-PCR and immunohistochemistry staining. The cell growth and colony formation were observed as the overexpression and knockdown of SFRP1. The DNA methylation status within SFRP1 promoter was analyzed through methylation-specific PCR or bisulphate-treated DNA sequencing assays. Loss of heterozygosity was here detected with microsatellite markers.</p> <p>Results</p> <p>SFRP1 was significantly down-regulated in 76.1% (35/46) HCC specimens at mRNA level and in 30% (30/100) HCCs indicated by immunohistochemistry staining, as compared to adjacent non-cancerous livers. The overexpression of SFRP1 can significantly inhibit the cell growth and colony formation of YY-8103, SMMC7721, and Hep3B cells. The RNA interference against the constitutional SFRP1 in the offspring SMMC7721 cells, which were stably transfected by ectopic SFRP1, can markedly promote cell growth of these cells. LOH of both microsatellite markers D8S532 and D8SAC016868 flanking the gene locus was found in 13% (6 of 46 HCCs) and 6.5% (3 of 46 HCCs) of the informative cases, respectively, where 5 of 8 HCC specimens with LOH showed the down-regulation of SFRP1. DNA hypermethylation within SFRP1 promoter was identified in two of three HCC specimens without SFRP1 expression. Moreover, the DNA methylation of SFRP1 promoter was significantly reduced, along with the re-expression of the gene, in those HCC cell lines, Bel7404, QGY7701, and MHCC-H, as treated by DAC.</p> <p>Conclusion</p> <p>Our data suggested that the down-regulation of SFRP1 as a candidate tumor suppressor gene, triggered by the epigenetic and/or genetic events, could contribute to the oncogenesis of HCC.</p
Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion
Ludmilla T Domingos Chinen,1 Celso A Lopes Mello,2 Emne Ali Abdallah,1 Luciana MM Ocea,1 Marcilei E Buim,1 Natália M Breve,1 José Luiz Gasparini Junior,1 Marcello F Fanelli,2 Patrizia Paterlini-Bréchot3 1International Research Center, 2Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil; 3Unité INSERM U807, Université Paris Descartes, Paris, France Background: Sarcomas are rare and heterogeneous neoplasms with poor prognosis that are thought to spread to distant organs mainly by hematogenous dissemination. However, circulating tumor cells (CTCs) have never been visualized in sarcomas. Objectives: To investigate the feasibility of using isolation by size of tumor cells (ISET) for isolation, identification, and characterization of CTCs derived from patients with high-grade and metastatic sarcomas. Patients and methods: We studied eleven patients with metastatic/recurrent or locally advanced soft-tissue sarcomas (STSs), six of whom had synovial sarcomas. Blood samples (8 mL) were collected from patients with advanced STS and treated by ISET, a marker- independent approach that isolates intact CTCs from blood, based on their larger size compared with leukocytes. CTCs were identified by cytomorphology and characterized by dual-color immunocytochemistry using antivimentin or anti-Pan CK, and anti-CD45. Results: All patients with STS included in this study showed CTCs, with numbers ranging from two to 48 per 8 mL of blood. Conclusion: This study shows the feasibility of isolating, identifying, and characterizing CTCs from patients with different types of sarcomas and the presence of circulating sarcoma cells in all the tested patients. Our results set the basis for further studies aimed at exploring the presence, number, and immunomolecular characteristics of CTCs in different types of sarcoma, and bring more light to the mechanisms of tumor invasion for these tumors. Keywords: sarcoma, circulating tumor cells, ISET 
Cancers of the Urinary System
The role of translation and its regulation in cancers of the urinary system is poorly studied and understood, and is limited to investigations of the activity of eIF4E and its binding proteins (4E-BPs) in bladder cancer and, to a lesser extent, RCCs. The lack of studies on this topic is surprising given the established role of the mTOR signaling pathway, which converges on the translation machinery, in the pathobiology and therapeutic targeting in RCC. Nevertheless, the available body of evidence suggests involvement of eIF4E overexpression and activation via the mTOR/4E-BPs module in the biology of cancers of the urinary system. This chapter discusses the current state of our knowledge on alterations of the translation machinery in these malignancie